Human-gene patent ruling could hurt pharma, gene-testing industry

06/14/2013 | Denver Post, The · HealthDay News · Reuters · Yahoo

The Supreme Court's decision Thursday that naturally occurring human genes can't be patented could have broad implications for the pharmaceutical, biotech and gene-testing industries. Critics said the ruling would not only hurt Myriad Genetics, but also the bottom line of companies that sell genetic tests. It could also discourage investment in genetic sequencing research. "The Supreme Court's decision today represents a troubling departure from decades of judicial and Patent and Trademark Office precedent," BIO President and CEO Jim Greenwood said.

View Full Article in:

Denver Post, The · HealthDay News · Reuters · Yahoo

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Chief Executive Officer
UCare Minnesota
Minneapolis, MN